Items where contributor is "Rochlitz, Christoph"

Group by: Date | Item Type | Refereed | No Grouping

Article

Romer, A. and Seiler, D. and Marincek, N. and Brunner, P. and Koller, M. T. and Ng, Q. K. T. and Maecke, H. R. and Müller-Brand, J. and Rochlitz, C. and Briel, M. and Schindler, C. and Walter, M. A.. (2014) Somatostatin-based radiopeptide therapy with [(177)Lu-DOTA]-TOC versus [ (90)Y-DOTA]-TOC in neuroendocrine tumours. European journal of nuclear medicine and molecular imaging, Vol. 41, H. 2. pp. 214-222.

Marincek, N. and Jorg, A. C. and Brunner, P. and Schindler, C. and Koller, M. T. and Rochlitz, C. and Muller-Brand, J. and Maecke, H. R. and Briel, M. and Walter, M. A.. (2013) Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors : long-term outcome of a phase I dose escalation study. Journal of translational medicine, Vol. 11 , 17. p. 17.

Bontognali, S. and Pless, M. and Brutsche, M. H. and Fischer, C. and Rochlitz, C. and Buess, M.. (2013) Analysis of the EGFR mutation status in head and neck squamous cell carcinoma before treatment with Gefitinib. Onkologie, 36 (4). pp. 161-166.

Wicki, Andreas and Rochlitz, Christoph and Orleth, Annette and Ritschard, Reto and Albrecht, Imke and Herrmann, Richard and Christofori, Gerhard and Mamot, Christoph. (2012) Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth. Clinical cancer research, Vol. 18, no. 18. pp. 454-464.

Wicki, A. and Rochlitz, C.. (2012) Targeted therapies in breast cancer. Swiss medical weekly, Vol. 142 , w13550.

Mamot, C. and Ritschard, R. and Wicki, A. and Kung, W. and Schuller, J. and Herrmann, R. and Rochlitz, C.. (2012) Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells. Journal of drug targeting, Vol. 20, H. 5. pp. 422-432.

Mamot, C. and Ritschard, R. and Wicki, A. and Stehle, G. and Dieterle, T. and Bubendorf, L. and Hilker, C. and Deuster, S. and Herrmann, R. and Rochlitz, C.. (2012) Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. The Lancet oncology, Vol. 13, H. 12. pp. 1234-1241.

Imhof, A. and Brunner, P. and Marincek, N. and Briel, M. and Schindler, C. and Rasch, H. and Macke, H. R. and Rochlitz, C. and Muller-Brand J., and Walter, M. A.. (2011) Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 29, H. 17. pp. 2416-2423.

Schmid, S. M. and Myrick, M. E. and Forrer, F. and Obermann, E. C. and Viehl, C. T. and Rochlitz, C. and Güth, U.. (2011) Sentinel lymph node biopsy in primary breast cancer : trust the radiolabeled colloid method and avoid unnecessary procedures. European journal of surgical oncology, Vol. 37, H. 3. pp. 211-216.

Rochlitz, C. and Ruhstaller, T. and Lerch, S. and Spirig, C. and Huober, J. and Suter, T. and Buhlmann, M. and Fehr, M. and Schonenberger, A. and von Moos, R. and Winterhalder, R. and Rauch, D. and Muller, A. and Mannhart-Harms, M. and Herrmann, R. and Cliffe, B. and Mayer, M. and Zaman, K.. (2011) Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer : a multicenter, single-arm phase II trial (SAKK 24/06). Annals of Oncology, Vol. 22, H. 1. pp. 80-85.

Huober, Jens and Baumann, Michael and Rochlitz, Christoph and Aebi, Stefan and Güth, Uwe and von Moos, Roger and Müller, Andreas and von Rohr, Lukas and Widmer, Isabelle and Thürlimann, Beat. (2011) Trastuzumab treatment beyond progression in advanced breast cancer : patterns of care in six Swiss breast cancer centers. Oncology, 81 (3-4). pp. 160-166.

Vetter, Marcus and Tzankov, Alexandar and Engert, Andreas and Mehling, Matthias and Herrmann, Richard and Rochlitz, Christoph. (2011) Hodgkin's Lymphoma and Paraneoplastic Phenomena in the Central Nervous System : A Case Report and Review of the Literature. Case Reports in Oncology, 4 (1). pp. 106-114.

Rajski, M. and Zanetti-Dallenbach, R. and Vogel, B. and Herrmann, R. and Rochlitz, C. and Buess, M.. (2010) IGF-I induced genes in stromal fibroblasts predict the clinical outcome of breast and lung cancer patients. BMC medicine, Vol. 8. p. 1.

Iten, Fabienne and Muller, Beat and Schindler, Christian and Rasch, Helmut and Rochlitz, Christoph and Oertli, Daniel and Maecke, Helmut R. and Muller-Brand, Jan and Walter, Martin A.. (2009) [(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: long-term results of a phase 2 clinical trial. Cancer, 115 (10). pp. 2052-2062.

Buess, Martin and Rajski, Michal and Vogel-Durrer, Brigitte M. L. and Herrmann, Richard and Rochlitz, Christoph. (2009) Tumor-endothelial interaction links the CD44(+)/CD24(-) phenotype with poor prognosis in early-stage breast cancer. Neoplasia, Vol. 11. pp. 987-1002.

Güth, Uwe and Huang, Dorothy Jane and Dirnhofer, Stephan and Rochlitz, Christoph and Wight, Edward. (2009) Distant metastatic breast cancer as an incurable disease : a tenet with a need for revision. The cancer journal : the official journal of the American Radium Society, Vol. 15. pp. 81-86.

Aprili, Daniel and Bandschapp, Oliver and Rochlitz, Christoph and Urwyler, Albert and Ruppen, Wilhelm. (2009) Serious complications associated with external intrathecal catheters used in cancer pain patients : a systematic review and meta-analysis. Anesthesiology, Vol. 111, H. 6. pp. 1346-1355.

Gross, M. and Obermann, E. and Weinand, K. and Zimmermann, F. and Rochlitz, C.. (2008) Der aktuelle Stand beim invasiven, nicht hämatogen metastasierten Mammakarzinom. InfoOnkologie, Vol. 11. pp. 595-605.

Dummer, R. and Rochlitz, C. and Velu, T. and Acres, B. and Limacher, J. M. and Bleuzen, P. and Lacoste, G. and Slos, P. and Romero, P. and Urosevic, M.. (2008) Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma. Molecular therapy, Vol. 16, H. 5. pp. 985-994.